A Combination of Glutaminase Inhibitor 968 and PD-L1 Blockade Boosts the Immune Response against Ovarian Cancer
出版年份 2021 全文链接
标题
A Combination of Glutaminase Inhibitor 968 and PD-L1 Blockade Boosts the Immune Response against Ovarian Cancer
作者
关键词
-
出版物
Biomolecules
Volume 11, Issue 12, Pages 1749
出版商
MDPI AG
发表日期
2021-11-24
DOI
10.3390/biom11121749
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A novel co-culture assay to assess anti-tumor CD8+ T cell cytotoxicity via luminescence and multicolor flow cytometry
- (2020) Verónica Olivo Pimentel et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer
- (2020) Deanna N. Edwards et al. JOURNAL OF CLINICAL INVESTIGATION
- Immunotherapy in ovarian cancer: fake news or the real deal?
- (2019) Christian Marth et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Glutamine Addiction and Therapeutic Strategies in Lung Cancer
- (2019) Karolien Vanhove et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Peripheral T cell cytotoxicity predicts T cell function in the tumor microenvironment
- (2019) Kota Iwahori et al. Scientific Reports
- Enhancing tumor T cell infiltration to enable cancer immunotherapy
- (2019) Jin Zhang et al. Immunotherapy
- Anti-PD-L1 treatment results in functional remodeling of the macrophage compartment
- (2019) Huizhong Xiong et al. CANCER RESEARCH
- Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion
- (2019) Robert D. Leone et al. SCIENCE
- CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation – A target for novel cancer therapy
- (2018) Ryuma Tokunaga et al. CANCER TREATMENT REVIEWS
- Characterization of the interactions of potent allosteric inhibitors with glutaminase C, a key enzyme in cancer cell glutamine metabolism
- (2018) Qingqiu Huang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)
- (2018) Young Kwang Chae et al. Journal for ImmunoTherapy of Cancer
- Patient inflammatory status and CD4+/CD8+ intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer
- (2018) Mauricio P. Pinto et al. GYNECOLOGIC ONCOLOGY
- Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy
- (2018) Yiyi Yan et al. Frontiers in Immunology
- Reinforce the antitumor activity of CD8+ T cells via glutamine restriction
- (2018) Shogo Nabe et al. CANCER SCIENCE
- Distinct Regulation of Th17 and Th1 Cell Differentiation by Glutaminase-Dependent Metabolism
- (2018) Marc O. Johnson et al. CELL
- Metabolic rewiring beyond Warburg in chronic lymphocytic leukemia: How much do we actually know?
- (2018) Gabriela Galicia-Vázquez et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Prognostic value of tumor PD-L1 expression combined with CD8 + tumor infiltrating lymphocytes in high grade serous ovarian cancer
- (2017) Qiaohong Wang et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- PD-L1
- (2017) Anthousa Kythreotou et al. JOURNAL OF CLINICAL PATHOLOGY
- Carboplatin and programmed death-ligand 1 blockade synergistically produce a similar antitumor effect to carboplatin alone in murine ID8 ovarian cancer model
- (2017) Xinxin Zhu et al. JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH
- GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses
- (2017) Zefang Tang et al. NUCLEIC ACIDS RESEARCH
- Interferon-inducible CXC-chemokines are crucial immune modulators and survival predictors in colorectal cancer
- (2017) Larissa Kistner et al. Oncotarget
- CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer
- (2016) Holger Bronger et al. BRITISH JOURNAL OF CANCER
- Cytotoxic T Cells and Granzyme B Associated with Improved Colorectal Cancer Survival in a Prospective Cohort of Older Women
- (2016) Anna E. Prizment et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Calreticulin Expression in Human Non–Small Cell Lung Cancers Correlates with Increased Accumulation of Antitumor Immune Cells and Favorable Prognosis
- (2016) Jitka Fucikova et al. CANCER RESEARCH
- Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells
- (2016) Naoki Horikawa et al. CLINICAL CANCER RESEARCH
- Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma
- (2016) Adil I. Daud et al. JOURNAL OF CLINICAL INVESTIGATION
- Chemoattractant Receptors BLT1 and CXCR3 Regulate Antitumor Immunity by Facilitating CD8+T Cell Migration into Tumors
- (2016) Zinal S. Chheda et al. JOURNAL OF IMMUNOLOGY
- Upregulation of granzyme B and interferon-γ mRNA in responding lesions by treatment with nivolumab for metastatic melanoma: a case report
- (2016) H. Anegawa et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint
- (2016) Shaohua Xu et al. Nature Communications
- A novel glutaminase inhibitor-968 inhibits the migration and proliferation of non-small cell lung cancer cells by targeting EGFR/ERK signaling pathway
- (2016) Tianyu Han et al. Oncotarget
- Altered glutamine metabolism in platinum resistant ovarian cancer
- (2016) Chantelle D. Hudson et al. Oncotarget
- Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor- B to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer
- (2015) J. Peng et al. CANCER RESEARCH
- Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
- (2015) Junzo Hamanishi et al. JOURNAL OF CLINICAL ONCOLOGY
- Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy
- (2015) Rosa Barreira da Silva et al. NATURE IMMUNOLOGY
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Kidney-type glutaminase (GLS1) is a biomarker for pathologic diagnosis and prognosis of hepatocellular carcinoma
- (2015) Decai Yu et al. Oncotarget
- Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer
- (2014) L. Yang et al. Molecular Systems Biology
- Therapeutic PD-1 Pathway Blockade Augments with Other Modalities of Immunotherapy T-Cell Function to Prevent Immune Decline in Ovarian Cancer
- (2013) J. Duraiswamy et al. CANCER RESEARCH
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- (2012) J. M. Taube et al. Science Translational Medicine
- Immune Response in Ovarian Cancer: How Is the Immune System Involved in Prognosis and Therapy: Potential for Treatment Utilization
- (2011) Nikos G. Gavalas et al. Clinical & Developmental Immunology
- CXCR3 ligands: redundant, collaborative and antagonistic functions
- (2011) Joanna R Groom et al. IMMUNOLOGY AND CELL BIOLOGY
- The chemokine system and cancer
- (2011) Frances R Balkwill JOURNAL OF PATHOLOGY
- Inhibition of Granzyme B by PI-9 protects prostate cancer cells from apoptosis
- (2011) Manisha Ray et al. PROSTATE
- Targeting Mitochondrial Glutaminase Activity Inhibits Oncogenic Transformation
- (2010) Jian-Bin Wang et al. CANCER CELL
- Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer
- (2009) R J DeBerardinis et al. ONCOGENE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started